August 25, 2006 -- Two days after publishing a potential breakthrough in the creation of stem cell lines, Advanced Cell Technology announced two separate refinancing initiatives; Corlux, an anti-psychotic drug from Corcept, failed the first of three Phase III trials; Shire filed for approval of an extended release form of guanfacine for ADHD; Dyax exchanged future revenues for $30 million; and Novogen can begin a Phase III test of its ovarian cancer drug phenoxodiol. The Centient Biotech 200™ gained 10 points to end at 3689.25, a rise of .28%. More details...
